• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Poll results: How comfortable are you with including biosimilars in your treatment plans?

Poll

See the results from our recent poll!

Optometry Times asked our audience, "How comfortable are you with including biosimilars in your treatment plans?" and the results are in!

The poll appeared on OptometryTimes.com and was promoted across social channels from Feb. 15 to Feb. 22, 2023.

10 ODs responded:

- 4 said, "Very excited to begin embracing biosimilars"

- 4 said, "Feeling comfortable exploring biosimilar options, though cautiously"

- 0 said, "Still hesitant, I need to learn more about biosimilars"

- 2 said, "With the knowledge of biosimilars I have, I am not comfortable including this in my treatment plans"

To learn more about biosimilars for AMD, check out Euin Cheong, OD's piece on "Introduction to biosimilars for AMD."

Related Videos
Dr. John Sheppard discusses results from trials testing the efficacy of eye drops to treat dry eye disease
Kelsey Roelofs, MD, details the best methods to identify thyroid eye disease at CIME 2024
David A. Berntsen, OD, PhD, FAAO, outlines his presentation on the BLINK 2 study presented at the 2024 ARVO meeting
Marc Bloomenstein, OD's Insights from CIME on Diagnosing and Treating Demodex Blepharitis
James Katz, MD, talks Demodex blepharitis treatment options in CIME presentation
© 2024 MJH Life Sciences

All rights reserved.